Duchenne News Tags: Capricor Therapeutics

On July 22, 2025, Capricor Therapeutics provided a Community Letter with updates on the regulatory status of deramiocel, their investigational cell therapy for the treatment of cardiomyopathy associated with Duchenne...

On June 24, 2025, Capricor Therapeutics provided regulatory updates related to its Biologics License Application (BLA) for Deramiocel, the Company’s lead cell therapy candidate for the treatment of Duchenne Muscular...

On June 11, 2025, Capricor Therapeutics announced the successful completion of the U.S. Food and Drug Administration’s (FDA) Pre-License Inspection (PLI) of its SanDiego manufacturing facility for Deramiocel, the Company’s...

On June 28, 2024, Capricor Therapeutics announced additional positive 3-year safety and efficacy results from its ongoing HOPE-2 open label extension (OLE) study with its lead asset, deramiocel (CAP-1002), for...

Patients treated with CAP-1002 continue to show positive benefits after 3 years of treatment in both the PUL 2.0 and LVEF measures when compared to an external comparator dataset of...

Capricor Therapeutics announces update on next steps for the Biologics License Application submission with its lead asset CAP-1002 in treating Duchenne muscular dystrophy.